New data in diabetic obese/overweight patients look positive for lorcaserin
This article was originally published in Scrip
In the wake of the recent US complete response letter for their weight loss product Lorqess (lorcaserin), Arena Pharmaceuticals and Eisai have released positive top-line results from a Phase III clinical trial with the product in obese and overweight patients with type 2 diabetes.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.